LIQUID BIOPSY IS REVOLUTIONIZING CANCER TREATMENT. NRICHDX EMPOWERS THAT REVOLUTION.

Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 19 Feb 2026)

What this means for you

Registered since 03 Nov 2020. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
88250571
Registration number
6190469
Mark type
Stylized text
Filed
04 Jan 2019
Published for opposition
07 May 2019
Registered
03 Nov 2020
Attorney of record
Matthew A. Newboles

Goods and services

  • Class 010 — Medical apparatus: cell culture and cancer diagnostics tests, namely, liquid biopsy testing systems consisting of a specimen chamber assembly and magnetic materials used to sequester target analytes of interest within a liquid sample for isolation and characterization

Owner

Prosecution history

  • 19 Feb 2026 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
  • 19 Feb 2026 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
  • 19 Feb 2026 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
  • 14 Nov 2025 — TEAS SECTION 8 & 15 RECEIVED
  • 03 Nov 2025 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
  • 03 Nov 2020 — REGISTERED-PRINCIPAL REGISTER
  • 02 Oct 2020 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
  • 01 Oct 2020 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
  • 18 Sept 2020 — STATEMENT OF USE PROCESSING COMPLETE
  • 02 Sept 2020 — USE AMENDMENT FILED
  • 18 Sept 2020 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
  • 02 Sept 2020 — TEAS STATEMENT OF USE RECEIVED
  • 04 Jul 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 02 Jul 2020 — SOU EXTENSION 2 GRANTED
  • 02 Jul 2020 — SOU EXTENSION 2 FILED

View this trademark record on Marksy